FDA Accepts Bristol Myers Squibb’s NDA for Mezigdomide in Relapsed Multiple Myeloma — Bristol-Myers Squibb Company

Event summary

FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) for relapsed/refractory multiple myeloma.
PDUFA target action date set for May 13, 2027.
Phase 3 SUCCESSOR-2 trial showed MeziKd reduced risk of disease progression or death by 52% vs. Kd (HR: 0.48; p<0.0001).
Mezigdomide is an oral cereblon E3 ligase modulator (CELMoD) optimized for rapid degradation of Ikaros and Aiolos proteins.

The big picture

Bristol Myers Squibb is advancing its leadership in targeted protein degradation with mezigdomide, a next-generation CELMoD. The FDA’s NDA acceptance underscores the company’s strategic focus on addressing unmet needs in relapsed/refractory multiple myeloma, where treatment options remain limited. Success here could further solidify BMS’s position in hematologic malignancies while expanding its pipeline into broader oncology applications.

What we're watching

Regulatory Timing: Whether the FDA will approve MeziKd by the May 2027 PDUFA date, given the strong Phase 3 data.
Pipeline Momentum: How Bristol Myers Squibb’s targeted protein degradation platform progresses beyond hematology into solid tumors.
Competitive Positioning: The pace at which MeziKd could capture market share in the relapsed/refractory multiple myeloma space, particularly among triple-class-exposed patients.